Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Identifies Need For Updated Chemical-Evaluation Processes In CFSAN

This article was originally published in The Tan Sheet

Executive Summary

FDA says it will look to update processes across CFSAN divisions, including its cosmetics office, for assessing and sharing information related to chemical hazards, following completion of a review that included interviews with current and former FDAers and consultation with outside experts. In its report, CFSAN prioritizes an in silico system that would house chemical-risk-assessment data and use predictive tools to provide centers with safety signals related to substances used in cosmetics, dietary supplements and other regulated products.

Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS107273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel